Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics says ovarian cancer drug shows benefit in mid-stage study

March 21 (Reuters) - Oncolytics Biotech  
    * Update for randomized phase ii clinical trial reolysin in 
combination with paclitaxel in patients with ovarian cancer 
    * Performed an intent-to-treat analysis of tumour response, 
which showed statistically significantly higher full response 
rates 
 
Source text for Eikon:  ID:nCNWsCbgka  
Further company coverage:  ONC.TO  
 
 (Bengaluru Newsroom: +1-646-223-8780)

Recent news on Oncolytics Biotech

See all news